Acepodia announces first patient dosed in Phase 1 trial of ACE723
The first patient was dosed at a clinical trial site in China on November 5, 2026, marking the first human exposure of ACE723, a GPC3-targeted dual-payload antibody-drug conjugate. ACE723 received IND clearance from the FDA and China's NMPA in September 2026 and TFDA approval in October 2026.
Primary source
Company press release (PR Newswire), November 5, 2026
Acepodia Announces First Patient Dosed in Phase 1 Trial of ACE723, a Novel Dual-Payload Antibody-Drug Conjugate
Read the source: Acepodia Announces First Patient Dosed in Phase 1 Trial of ACE723, a Novel Dual-Payload Antibody-Drug Conjugate prnewswire.com
Machine-summarized from the source above; not independently reported. How we use automation